Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
The Miami Myeloma MRD 2025 Meeting was hosted by the Myeloma Institute at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, in collaboration with the Multiple Myeloma Research Foundation (MMRF), International Myeloma Foundation (IMF), HealthTree Foundation for Multiple Myeloma and World Health Communications, with VJHemOnc as official media partner.
The Miami Myeloma 2025 Workshop was supported by AstraZeneca, GSK, Abbvie, Adaptive, Johnson & Johnson, Pfizer, Sanofi, Bristol Myers Squibb and Sebia. Supporters have no influence on the production of content.
The workshop was held on April 11, 2025, and brought together leading experts in multiple myeloma to discuss the use of measurable residual disease (MRD) in clinical and trial settings, furthering our understanding of recent advances, and encouraging interactive discussion.
Explore roundtable discussions
View all videos
MRD as an early endpoint for accelerated approval
The evolution of MRD negativity in newly diagnosed myeloma
MRD driven clinical trials
The use of MRD in MMRFs clinical program
Emerging MRD technologies
